Perspective Therapeutics
CATX
29 hedge funds and large institutions have $1.62M invested in Perspective Therapeutics in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 6 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.14% less ownership
Funds ownership: 0.73% → 0.59% (-0.14%)
9% less funds holding
Funds holding: 32 → 29 (-3)
11% less capital invested
Capital invested by funds: $1.83M → $1.62M (-$207K)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$70.9K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$25.2K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.61K |
| 4 |
SIA
Starfire Investment Advisers
Southfield,
Michigan
|
+$3.14K |
| 5 |
BlackRock
New York
|
+$1.65K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$381K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$62K |
| 3 |
CWM
Cornerstone Wealth Management
St. Peters,
Missouri
|
-$42K |
| 4 |
Bank of New York Mellon
New York
|
-$24K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$8.48K |
CATX Hedge Fund Activity: Q2 2019 in Review
29 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q2 2019, worth a combined $1.62M — down 11% from $1.83M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CATX and 3 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $70.9K. The largest seller was Sabby Management, cutting an estimated $381K.
- 29 institutional investors held Perspective Therapeutics (CATX) as of Q2 2019, down from 32 in Q1 2019.
- Funds reported $1.62M of Perspective Therapeutics stock for Q2 2019, down 11% quarter-over-quarter.
- 3 funds opened new Perspective Therapeutics positions in Q2 2019 and 6 closed out, a net change of -3 holders.
- The largest Perspective Therapeutics buyer in Q2 2019 was Vanguard Group, an estimated $70.9K added.
- The largest Perspective Therapeutics seller in Q2 2019 was Sabby Management, an estimated $381K sold.
Based on aggregated 13F filings for Q2 2019.